What Are Some of the Potential Drawbacks to Receiving an Investigational Drug?

Although investigational drugs can provide hope for cancer patients who may not be responding well to standard therapies, there are certainly drawbacks and risks associated with the opportunity. The process is associated with a whole gamut of unknowns, some of which could potentially be dangerous. Investigational drug drawbacks include the following:

Avoiding Risks With Investigational Risks

Although there’s no way to completely eliminate risks form the investigational drug equation, the protocols associated with actually obtaining said drugs can mitigate those risks. In particular, the minimum patient criteria for eligibility to receive an investigational drug can help narrow down the appropriate patient pool.

To be considered a candidate for receiving an investigational drug outside of a clinical trial drug investigation setting, physicians must establish that patients:

TD2 is a world-class drug development service that specializes in getting the most innovative oncology treatments to patients who have been let down by more traditional treatment options. We can help physicians fill out applications for patients to access investigational drugs and help doctors weigh the costs and benefits associated with a particular investigational drug for a particular patient. We can also provide information about important regulatory issues.